Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-06-2018 | Editorial

Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift!

Authors: Poul Flemming Høilund-Carlsen, Søren Hess, Thomas J. Werner, Abass Alavi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2018

Excerpt

Bone metastases represent a serious complication to several cancers, in particular breast, lung, and prostate cancer. Since their presence influences prognosis and management, they must be searched for. Thus, the introduction of skeletal radionuclide imaging with ¹⁸F-NaF (NaF) 55 years ago was a major achievement [1], as was its replacement, scintigraphy with bone-seeking phosphates [2], until computed tomography (CT), magnetic resonance imaging (MRI), and once again NaF in the shape of NaF-positron emission tomography/CT (NaF-PET/CT) began contending for precedence. However, this development took place gradually, without anybody asking the central questions: What are skeletal metastases, how do they arise, and how do we best discover them? …

Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332–4.PubMed

Subramanian G, McAfee JG, Bell EG, Blair RJ, O’Mara RE, Ralston PH. ^99mTc-labeled polyphosphate as a skeletal imaging agent. Radiology. 1972;102:701–4.CrossRefPubMed

Wikipedia. Bone metastases [Internet]; [cited 2017 Sep 6]. Available from: https://en.wikipedia.org/wiki/Bone_metastasis.

Mayo Clinic. Bone metastases [Internet]; [cited 2017 Sep 6]. Available from: http://www.mayoclinic.org/diseases-conditions/bone-metastasis/basics/definition/CON-20035450.

American Cancer Society. Finding Bone Metastases [Internet]; [cited 2017 Sep 6]. Available from: https://www.cancer.org/treatment/understanding-your-diagnosis/advanced-cancer/finding-bone-metastases.html.

Wikipedia. Bone marrow. [Internet]; [cited 2017 Sep 6]. Available from: https://en.wikipedia.org/wiki/Bone_marrow.

American Cancer Society. Guidelines for the Early Detection of Cancer [Internet]; [cited 2017 Sep 6]. Available from: https://www.cancer.org/healthy/find-cancer-early/cancer-screening-guidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html.

Cancer control: Early detection. WHO guide for effective programmes. Eds. WHO. WHO Press, World Health Organization, Switzerland 2007. ISBN: 92 4 154733 8.

International Agency for Research on Cancer. Cancer Screening in the European Union. Report on the implementation of the Council Recommendation on cancer screening. [Internet]; [cited 2017 Oct 10]. Available from: https://ec.europa.eu/health/sites/health/files/major_chronic_diseases/docs/2017_cancerscreening_2ndreportimplementation_en.pdf.

10.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed

11.

Danish Health Authority. Cancer pathways [Internet]; 2014 Jun [cited 2017 Sep 6]. Available from: https://www.sst.dk/en/disease-and-treatment/cancer/cancer-pathways.

12.

Sundhedsstyrelsen. Beskrivelser af indgange til pakkeforløb på kræftområdet [Internet]; 2017 Aug [cited 2017 Sep 6]. Available from: https://www.sst.dk/da/sygdom-og-behandling/kraeft/pakkeforloeb/beskrivelser.

13.

Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study European Urol 2014;65(6):1058-1066.

14.

Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RL, Navarria P, et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer. 2014;14:619. https://doi.org/10.1186/1471-2407-14-619.CrossRefPubMedPubMedCentral

15.

Kucharczyk MJ, Parpia S, Walker-Dilks C, Banfield L, Swaminath A. Ablative therapies in metastatic breast cancer: a systematic review. Breast Cancer Res Treat. 2017 Jul;164(1):13–25. https://doi.org/10.1007/s10549-017-4228-2.CrossRefPubMed

16.

David EA, Clark JM, Cooke DT, Melnikow J, Kelly K, Canter RJ. The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-small Cell Lung Cancer. J Thorac Oncol. 2017;S1556–0864(17):30683–4. https://doi.org/10.1016/j.jtho.2017.08.008.

17.

Basu S, Alavi A. Bone marrow and not bone is the primary site for skeletal metastasis: critical role of [18F]fluorodeoxyglucose positron emission tomography in this setting. J Clin Oncol. 2007;25:1297. author reply 1297-9CrossRefPubMed

18.

Basu S, Torigian D, Alavi A. Evolving concept of imaging bone marrow metastasis in the twenty-first century: critical role of FDG-PET. Eur J Nucl Med Mol Imaging. 2008;35:465–71.CrossRefPubMed

19.

Patel LR, Camacho DF, Shiozawa Y, Pienta KJ, Taichman RS. Mechanisms of cancer cell metastasis to bone: a multistep process. Future Oncol. 2011;7(11):1285–97.CrossRefPubMedPubMedCentral

20.

Rahim F, Hajisamani S, Mortaz E, Ahmadzadeh A, Shahjahani M, Shahrabi S, et al. Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone Marrow Res. 2014;2014:405920.

21.

Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, Penner NL, et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 2012;10(7):e1001363. https://doi.org/10.1371/journal.pbio.1001363.

22.

Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, et al. Prospective comparison of 99mTc-MDP Scintigraphy, combined 18F-NaF and 18F-FDG PET/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med. 2015;56(12):1862–8. https://doi.org/10.2967/jnumed.115.162610.CrossRefPubMed

23.

Langsteger W, Rezaee A, Pirich C, Beheshti M. 18F-NaF-PET/CT and 99mTc-MDP bone Scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med. 2016;46(6):491–501. https://doi.org/10.1053/j.semnuclmed.2016.07.003.CrossRefPubMed

24.

Löfgren J, Mortensen J, Rasmussen SN, et al. A prospective study comparing 99mTc-HDP planar bone scintigraphy and whole-body SPECT/CT with h18F–fluoride PET/CT and 18F–fluoride PET/MR for diagnosing bone metastases. J Nucl Med. 2017; https://doi.org/10.2967/jnumed.116.189183.

25.

Kwee TC, Basu S, Saboury B, Ambrosini V, Torigian DA, Alavi A. A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging. 2011;38:1158–70.CrossRefPubMed

26.

Krøigård AB, Larsen MJ, Brasch-Andersen C, et al. Genomic analyses of breast cancer progression reveal distinct routes of metastasis emergence. Sci Rep. 2017;7:43813. https://doi.org/10.1038/srep43813.CrossRefPubMedPubMedCentral

27.

Blebea JS, Houseni M, Torigian DA, Fan C, Mavi A, Zhuge Y, et al. Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med. 2007;37(3):185–94.CrossRefPubMed

28.

Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81(5):1007–15.CrossRefPubMed

29.

Caglar M, Kupik O, Karabulut E, Høilund-Carlsen PF. Detection of bone metastases in breast cancer patients in the PET/CT era: do we still need the bone scan? Rev Esp Med Nucl Imagen Mol. 2016;35(1):3–11.PubMed

30.

Hildebrandt MG, Gerke O, Baun C, Falch K, Hansen JA, Farahani ZA, et al. [18F]Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in suspected recurrent breast cancer: a prospective comparative study of dual-time-point FDG-PET/CT, contrast-enhanced CT, and bone Scintigraphy. J Clin Oncol. 2016;34(16):1889–97.

31.

Cheng G, Kwee TC, Basu S, Alavi A. Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease. Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1141–5.CrossRefPubMed

32.

Al-Muqbel KM. Bone marrow metastasis is an early stage bone metastasis in breast cancer detected clinically by F18-FDG-PET/CT imaging. Biomed Res Int. 2017;2017:9852632. https://doi.org/10.1155/2017/9852632.CrossRefPubMedPubMedCentral

33.

Gerke O, Hermansson R, Hess S, Schifter S, Vach W, Høilund-Carlsen PF. Cost-effectiveness of PET and PET/computed tomography: a systematic review. PET Clin. 2015;10(1):105–24.CrossRefPubMed

Title: Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift!
Authors: Poul Flemming Høilund-Carlsen
Søren Hess
Thomas J. Werner
Abass Alavi
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-3959-6

2024 ASCO Annual Meeting

Springer Medicine

Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift!

Excerpt

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2018

Hybrid MR-PET of brain tumours using amino acid PET and chemical exchange saturation transfer MRI

The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma

The relationship between local recurrences and distant metastases in prostate cancer: can 11C-choline PET/CT contribute to understand the link?

FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease

Imaging αvβ3 integrin expression in skeletal metastases with 99mTc-maraciclatide single-photon emission computed tomography: detection and therapy response assessment